Literature DB >> 11857315

Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ.

Claudia M Acevedo1, Marcela Henríquez, Michael R Emmert-Buck, Rodrigo F Chuaqui.   

Abstract

BACKGROUND: Despite the increasing frequency of adenocarcinomas of the uterine cervix, little is known regarding inactivation of tumor suppressor genes (TSGs) in this tumor type. The authors analyzed loss of heterozygosity (LOH) in 36 carcinomas of the cervix with glandular differentiation, and 5 adenocarcinoma in situ in 40 patients.
METHODS: The authors analyzed samples using laser capture microdissection from archival material and DNA amplified with microsatellite markers on the following loci: 3p14.2 (D3S1234, D3S1300), 3p21.3 (D3S1029, D3S1447), 3p22-24 (D3S1537, D3S1351), 6q21-23.3 (D6S250), 6q25.1 (ESR), 6q25.2 (D6S255), 8p21 (D8S136, D8S1820), 13q12.3 (D13S220, D13S267), 17q21 (D17S579, D17S855). Eight additional markers spanning the short arm of chromosome 3 (3p12-p25) and six spanning the long arm of chromosome 6 (6q11-q27) were studied in the cases showing LOH to further define the deletion intervals.
RESULTS: The frequency of allelic loss in cancers was chromosome 3p: 49% (p14.2: 35%, p21.3: 23%, p22-24: 41%), 6q: 48% (q21-23.1: 39%, q25.1: 45%, q25.2: 7%), 13q: 22%, 17q: 6%, and 8p: 18%. On chromosome arm 3p, the authors' data suggest at least two discrete areas of deletion: a proximal area between markers D3S1234 (p12) and D3S1766 (p14.2-14.3), and a second distal interval, telomeric from marker D3S4623 (p21.3). On chromosome 6q, the deletion area is between marker D6S300 (q22) and D6S255 (q25.2). Two of five preneoplastic lesions showed LOH on chromosome arm 3p, and two five showed allelic loss on chromosome arm on 6q, suggesting the genes might be inactivated early in cervical tumorigenesis.
CONCLUSIONS: The authors have identified three chromosomal regions that may harbor TSGs involved in the development/progression of adenocarcinomas of the uterine cervix, 3p12-14.2, 3p21.3-pter, and 6q22-25.2. Deletions also were detected in adenocarcinoma in situ, suggesting the genes may be inactivated early in cervical tumorigenesis. Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10275

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857315     DOI: 10.1002/cncr.10275

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Expression of MTLC gene in gastric carcinoma.

Authors:  Guang-Bin Qiu; Li-Guo Gong; Dong-Mei Hao; Zhi-Hong Zhen; Kai-Lai Sun
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

2.  Assessment of the frequency of genetic alterations (LOH/MSI) in patients with intraepithelial cervical lesions with HPV infection: a pilot study.

Authors:  Monika Migdalska-Sęk; Agata Karowicz-Bilińska; Dorota Pastuszak-Lewandoska; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska-Senderowska; Justyna Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-04-18       Impact factor: 3.064

3.  Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.

Authors:  Zhaohui Wang; Lili Li; Xianwei Su; Zifen Gao; Gopesh Srivastava; Paul G Murray; Richard Ambinder; Qian Tao
Journal:  J Transl Med       Date:  2012-10-11       Impact factor: 5.531

4.  Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing.

Authors:  Ling Qiu; Hao Feng; Hailin Yu; Ming Li; Yana You; Shurong Zhu; Wenting Yang; Hua Jiang; Xin Wu
Journal:  Genes (Basel)       Date:  2022-01-31       Impact factor: 4.096

5.  The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions.

Authors:  G Terry; L Ho; P Londesborough; P Cross; A Lopes; J Monaghan; J Cuzick
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.